EP1868618A2 - Compositions topiques comprenant plusieurs mono-et/ou oligosaccharides pour le traitement des maladies cutanees d ' animaux a sang chaud a pelage - Google Patents
Compositions topiques comprenant plusieurs mono-et/ou oligosaccharides pour le traitement des maladies cutanees d ' animaux a sang chaud a pelageInfo
- Publication number
- EP1868618A2 EP1868618A2 EP06726173A EP06726173A EP1868618A2 EP 1868618 A2 EP1868618 A2 EP 1868618A2 EP 06726173 A EP06726173 A EP 06726173A EP 06726173 A EP06726173 A EP 06726173A EP 1868618 A2 EP1868618 A2 EP 1868618A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- mono
- oligosaccharides
- oligosaccharide
- vectors
- adhesion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000002772 monosaccharides Chemical class 0.000 title claims abstract description 83
- 229920001542 oligosaccharide Polymers 0.000 title claims abstract description 67
- 150000002482 oligosaccharides Chemical class 0.000 title claims abstract description 67
- 239000000203 mixture Substances 0.000 title claims abstract description 60
- 241001465754 Metazoa Species 0.000 title claims abstract description 30
- 230000000699 topical effect Effects 0.000 title claims description 11
- 208000017520 skin disease Diseases 0.000 title claims description 3
- 210000004209 hair Anatomy 0.000 title abstract description 5
- 239000008280 blood Substances 0.000 title abstract 2
- 210000004369 blood Anatomy 0.000 title abstract 2
- 244000005700 microbiome Species 0.000 claims abstract description 19
- 239000013598 vector Substances 0.000 claims description 35
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims description 21
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical group OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 claims description 20
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 claims description 20
- PNNNRSAQSRJVSB-BXKVDMCESA-N aldehydo-L-rhamnose Chemical group C[C@H](O)[C@H](O)[C@@H](O)[C@@H](O)C=O PNNNRSAQSRJVSB-BXKVDMCESA-N 0.000 claims description 11
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 9
- 201000004624 Dermatitis Diseases 0.000 claims description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 6
- 208000006311 Pyoderma Diseases 0.000 claims description 6
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 6
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 6
- 125000002091 cationic group Chemical group 0.000 claims description 6
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 4
- SHZGCJCMOBCMKK-PQMKYFCFSA-N L-Fucose Natural products C[C@H]1O[C@H](O)[C@@H](O)[C@@H](O)[C@@H]1O SHZGCJCMOBCMKK-PQMKYFCFSA-N 0.000 claims description 4
- 201000008937 atopic dermatitis Diseases 0.000 claims description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 4
- 206010033072 otitis externa Diseases 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- SHZGCJCMOBCMKK-SVZMEOIVSA-N D-fucopyranose Chemical compound C[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O SHZGCJCMOBCMKK-SVZMEOIVSA-N 0.000 claims description 3
- SRBFZHDQGSBBOR-OWMBCFKOSA-N L-ribopyranose Chemical compound O[C@H]1COC(O)[C@@H](O)[C@H]1O SRBFZHDQGSBBOR-OWMBCFKOSA-N 0.000 claims description 3
- 241000555676 Malassezia Species 0.000 claims description 3
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 3
- 208000011580 syndromic disease Diseases 0.000 claims description 3
- 230000000622 irritating effect Effects 0.000 claims description 2
- GZCGUPFRVQAUEE-KVTDHHQDSA-N aldehydo-D-mannose Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O GZCGUPFRVQAUEE-KVTDHHQDSA-N 0.000 claims 2
- 210000003491 skin Anatomy 0.000 description 23
- 241000894006 Bacteria Species 0.000 description 12
- 210000000736 corneocyte Anatomy 0.000 description 11
- 244000000010 microbial pathogen Species 0.000 description 11
- 241000282472 Canis lupus familiaris Species 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 241000282465 Canis Species 0.000 description 5
- 102000003886 Glycoproteins Human genes 0.000 description 5
- 108090000288 Glycoproteins Proteins 0.000 description 5
- 241000589516 Pseudomonas Species 0.000 description 5
- 241000191980 Staphylococcus intermedius Species 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 150000001720 carbohydrates Chemical class 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 150000002402 hexoses Chemical class 0.000 description 5
- 210000002510 keratinocyte Anatomy 0.000 description 5
- 150000002972 pentoses Chemical class 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 229930186217 Glycolipid Natural products 0.000 description 4
- 230000000181 anti-adherent effect Effects 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 3
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 102000016359 Fibronectins Human genes 0.000 description 2
- 108010067306 Fibronectins Proteins 0.000 description 2
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 2
- 229920002396 Polyurea Polymers 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 239000012459 cleaning agent Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 239000003974 emollient agent Substances 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 238000010191 image analysis Methods 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000002085 irritant Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000003094 microcapsule Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000002453 shampoo Substances 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- 230000006433 tumor necrosis factor production Effects 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- OSDLLIBGSJNGJE-UHFFFAOYSA-N 4-chloro-3,5-dimethylphenol Chemical compound CC1=CC(O)=CC(C)=C1Cl OSDLLIBGSJNGJE-UHFFFAOYSA-N 0.000 description 1
- 244000291564 Allium cepa Species 0.000 description 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 1
- 239000004251 Ammonium lactate Substances 0.000 description 1
- 241000195940 Bryophyta Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-CBPJZXOFSA-N D-Gulose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O WQZGKKKJIJFFOK-CBPJZXOFSA-N 0.000 description 1
- WQZGKKKJIJFFOK-WHZQZERISA-N D-aldose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-WHZQZERISA-N 0.000 description 1
- WQZGKKKJIJFFOK-IVMDWMLBSA-N D-allopyranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@H](O)[C@@H]1O WQZGKKKJIJFFOK-IVMDWMLBSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- ZAQJHHRNXZUBTE-NQXXGFSBSA-N D-ribulose Chemical compound OC[C@@H](O)[C@@H](O)C(=O)CO ZAQJHHRNXZUBTE-NQXXGFSBSA-N 0.000 description 1
- ZAQJHHRNXZUBTE-UHFFFAOYSA-N D-threo-2-Pentulose Natural products OCC(O)C(O)C(=O)CO ZAQJHHRNXZUBTE-UHFFFAOYSA-N 0.000 description 1
- ZAQJHHRNXZUBTE-WUJLRWPWSA-N D-xylulose Chemical compound OC[C@@H](O)[C@H](O)C(=O)CO ZAQJHHRNXZUBTE-WUJLRWPWSA-N 0.000 description 1
- JDRSMPFHFNXQRB-CMTNHCDUSA-N Decyl beta-D-threo-hexopyranoside Chemical compound CCCCCCCCCCO[C@@H]1O[C@H](CO)C(O)[C@H](O)C1O JDRSMPFHFNXQRB-CMTNHCDUSA-N 0.000 description 1
- RPNUMPOLZDHAAY-UHFFFAOYSA-N Diethylenetriamine Chemical compound NCCNCCN RPNUMPOLZDHAAY-UHFFFAOYSA-N 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 229940124091 Keratolytic Drugs 0.000 description 1
- LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VSOAQEOCSA-N L-altropyranose Chemical compound OC[C@@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-VSOAQEOCSA-N 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 208000005141 Otitis Diseases 0.000 description 1
- 101001113927 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) PA-I galactophilic lectin Proteins 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010040952 Skin warm Diseases 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 1
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- SRBFZHDQGSBBOR-STGXQOJASA-N alpha-D-lyxopyranose Chemical compound O[C@@H]1CO[C@H](O)[C@@H](O)[C@H]1O SRBFZHDQGSBBOR-STGXQOJASA-N 0.000 description 1
- 229940059265 ammonium lactate Drugs 0.000 description 1
- 235000019286 ammonium lactate Nutrition 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- RZOBLYBZQXQGFY-HSHFZTNMSA-N azanium;(2r)-2-hydroxypropanoate Chemical compound [NH4+].C[C@@H](O)C([O-])=O RZOBLYBZQXQGFY-HSHFZTNMSA-N 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229910052729 chemical element Inorganic materials 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 229940080421 coco glucoside Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229940073499 decyl glucoside Drugs 0.000 description 1
- 239000002781 deodorant agent Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 1
- 229940047642 disodium cocoamphodiacetate Drugs 0.000 description 1
- 229960000878 docusate sodium Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 208000019258 ear infection Diseases 0.000 description 1
- SFNALCNOMXIBKG-UHFFFAOYSA-N ethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCO SFNALCNOMXIBKG-UHFFFAOYSA-N 0.000 description 1
- 229940071106 ethylenediaminetetraacetate Drugs 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 229960004068 hexachlorophene Drugs 0.000 description 1
- ACGUYXCXAPNIKK-UHFFFAOYSA-N hexachlorophene Chemical compound OC1=C(Cl)C=C(Cl)C(Cl)=C1CC1=C(O)C(Cl)=CC(Cl)=C1Cl ACGUYXCXAPNIKK-UHFFFAOYSA-N 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 150000002454 idoses Chemical class 0.000 description 1
- 230000009474 immediate action Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000001530 keratinolytic effect Effects 0.000 description 1
- 239000003410 keratolytic agent Substances 0.000 description 1
- BJHIKXHVCXFQLS-PQLUHFTBSA-N keto-D-tagatose Chemical compound OC[C@@H](O)[C@H](O)[C@H](O)C(=O)CO BJHIKXHVCXFQLS-PQLUHFTBSA-N 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 230000000503 lectinlike effect Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 235000011929 mousse Nutrition 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 239000002077 nanosphere Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- BTSZTGGZJQFALU-UHFFFAOYSA-N piroctone olamine Chemical compound NCCO.CC(C)(C)CC(C)CC1=CC(C)=CC(=O)N1O BTSZTGGZJQFALU-UHFFFAOYSA-N 0.000 description 1
- 229940081510 piroctone olamine Drugs 0.000 description 1
- 229920006122 polyamide resin Polymers 0.000 description 1
- 229920005668 polycarbonate resin Polymers 0.000 description 1
- 239000004431 polycarbonate resin Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 210000000106 sweat gland Anatomy 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229960003500 triclosan Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000011670 zinc gluconate Substances 0.000 description 1
- 229960000306 zinc gluconate Drugs 0.000 description 1
- 235000011478 zinc gluconate Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to compositions for topical application, said compositions being able to limit the adhesion of microorganisms on the skin of warm-blooded animals with peeling. It also relates to uses of such compositions in the veterinary field.
- the skin of animals is constantly attacked by pathogenic micro-organisms.
- the horny layer of the epidermis by its pH, its relatively low water content and the presence of antibiotic peptides having a bactericidal action, acts as the first barrier against these pathogenic microorganisms.
- Antibiotics can effectively fight against these pathogenic microorganisms, thanks to their bacteriostatic and / or bactericidal actions.
- the surface of certain bacteria is known to contain lectins, which enable them to recognize and bind to specific sugar radicals specific to glycoproteins and glycolipids located on the surface of epithelial cells. It has been demonstrated, in vitro, that by mimicking the sweet radicals of the glycoproteins and glycolipids of epithelial cells, certain saccharides limit the adhesion of bacteria such as Pseudomonas aeruginosa to glycoproteins such as fibronectins ("Inhibition of Pseudomonas aeruginosa adhesion to fibronectin by PA-IL and monosaccharides: "Involvement of a lectin-like process", Julie Rebiere-Huet, Patrick Di Martino, and Christian Hulen, Can J.
- the solution of the invention to this problem has as its first object a composition for topical application, characterized in that it comprises at least a first and a second mono- or oligosaccharide, each of said first and second mono- or oligosaccharides being capable of limiting the adhesion of microorganisms to the skin of warm-blooded animals with peeling.
- the pathogenic microorganisms in particular considered are Staphylococcus intermedius, Pseudomonas aeruginosa and Malassezia. pachydermatis.
- warm-blooded animals and pets are pets and especially dogs, cats or horses.
- Its second object is the use of a first and a second mono- or oligosaccharide, each of said first and second mono- or oligosaccharides being able to limit the adhesion of microorganisms, for the preparation of a composition topical for prevention, for the control or treatment of cutaneous disorders of warm-blooded animals.
- composition comprising charged micro- or nanoparticulate vectors, unloaded micro- or nanoparticulate vectors, said vectors comprising at least one active agent such as a mono- or oligosaccharide.
- a composition comprises at least two mono- or oligosaccharides each of said mono- or oligosaccharides being able to limit the adhesion of microorganisms, the inhibition of microorganisms affects a much larger number families and one Effective inhibition of microorganisms is observed so that the adhesion of pathogenic microorganisms to the skin of warm-blooded animals is greatly diminished.
- the addition of a third mono- or oligosaccharide is still very advantageous. Nevertheless, the addition of many other mono- or oligosaccharides would show little use.
- composition according to the invention comprises at least a first and a second mono- or oligosaccharide, said first mono- or oligosaccharide being different from said second mono- and / or oligosaccharide.
- Monosaccharides are molecules made up of three chemical elements: carbon, hydrogen and oxygen. They contain from 3 to 8 carbon atoms.
- pentoses such as arabinose, ribose, ribulose, xylose, xylulose and lyxose
- hexoses such as allose, altrose, fructose, galactose, glucose, gulose, idose, mannose, rhamnose, sorbose, talose and tagatose.
- the oligosaccharides are homogeneous or heterogeneous oligomers consisting of the abovementioned monosaccharides. In practice, it is di-, tri- or tetramers of monosaccharides.
- the first and second mono- or oligosaccharides are each capable of preventing and / or limiting the adhesion of microorganisms on the skin of warm-blooded animals, in particular on keratinocytes of the skin of these animals and, more particularly, to the corneocytes of the skin of these animals.
- they mimic the sweet radicals of glycoproteins and glycolipids, compete with these glycoproteins and glycolipids, and thus prevent the attachment of bacteria and yeasts.
- the invention makes it possible to prevent or limit the process of colonization and infection of pathogenic microorganisms on warm-blooded animals with peel. .
- pentoses and hexoses will advantageously be chosen.
- pentoses mention may be made of D-arabinose.
- hexoses mention may be made of D-fucose, L-fucose, D-galactose, D-glucose, D-mannose and L-rhamnose.
- first or second oligosaccharides capable of entering into the compositions according to the invention
- homogeneous or heterogeneous oligomers consisting of the abovementioned monosaccharides will advantageously be chosen.
- composition according to the invention further comprises a third mono- or oligosaccharide, said third mono- or oligosaccharide being different from said first and second mono- or oligosaccharides.
- This third mono- or oligosaccharide is advantageously itself able to limit the adhesion of microorganisms on the skin of warm-blooded animals with peel.
- the third mono- or oligosaccharide according to the invention is a monosaccharide, it is advantageously chosen from pentoses and hexoses.
- pentoses mention may be made of D-arabinose.
- hexoses mention may be made of D-fucose, L-fucose, D-galactose, D-glucose, D-mannose and L-rhamnose.
- homogeneous or heterogeneous oligomers consisting of the abovementioned monosaccharides will advantageously be chosen.
- the first, second and / or third mono- or oligosaccharides are advantageously capable of reducing the production of TNF- ⁇ by the keratinocytes of the skin of warm-blooded animals with peel. It will be noted that this action on TNF- ⁇ production has recently been demonstrated, in vitro, on canine keratinocytes ("in vitro assays for canine keratinocyte activation: modulation by fucose, arabinose and rhamnose", C. Ibisch, P. Bourdeau, C. Cadiot and H. Gatto, 17th ESVD-ECVD Congress, Copenhagen 2001). The decrease in TNF- ⁇ production has an immunomodulatory effect and leads to a decrease in cutaneous inflammation.
- the first mono- or oligosaccharide of the composition according to the invention is L-rhamnose or a homogeneous oligomer consisting of L-rhamnose
- the second mono- or oligosaccharide of the composition according to the invention is D-galactose or a homogeneous oligomer consisting of D-galactose
- the third mono- or oligosaccharide of the composition according to the invention is D-mannose or a homogeneous oligomer consisting of D-mannose.
- the composition according to the invention also advantageously comprises an alkylpolyglucoside.
- the alkylpolyglucosides (APG) according to the invention are substances consisting of one or more residues of glucose and an alkyl group, resulting from the condensation of a fatty alcohol with glucose or one of its polymers.
- the alkylpolyglucosides according to the invention are capable of preventing and / or limiting the adhesion of certain microorganisms, such as, in particular, Staphylococcus intermedius, to the skin of warm-blooded animals with fur.
- the presence of such alkylpolyglucosides in the compositions according to the invention therefore makes it possible to broaden the inhibitory action of adhesion to a wider range of microorganisms that are only slightly or not sensitive to the antiadhesive properties of mono- or oligosaccharides.
- the alkylpolyglucoside used in the composition according to the invention is lauryl diglucoside.
- the first, second and / or third mono- or oligosaccharides and / or the alkylpolyglucoside are advantageously contained in micro- or nanoparticulate vectors.
- 5 to 90% of the mono- or oligosaccharides and / or the alkylpolyglucoside are contained in these vectors.
- micro- or nanoparticulate vectors it is possible to use all the vectorization systems allowing a controlled release of the mono- or oligosaccharides according to the invention such as microcapsules, microspheres, macromolecular complexes, nanospheres, nanocapsules, latexes or the vesicles.
- micro or nanoparticulate vectors By way of non-limiting examples of micro or nanoparticulate vectors, mention may be made of the multilammellar vesicles sold by NOVAVAX TM under the name Novasomes TM, spherical multilamellar vesicles with onion structure called Spherulites TM, polyurethane-based microcapsules , polyurea resin, polyamide resin, polyamide-polyurea resin, polycarbonate resin, polysulfonate resin and polysulfonamide resin.
- the Spherulites TM can encapsulate hydrophilic or hydrophobic molecules with encapsulation efficiencies of the order of 90%. The molecules they encapsulate are released gradually. The release of the encapsulated compounds can be regulated kinetically or thermodynamically.
- the micro or nanoparticulate vectors according to the invention have a diameter of between 0.01 ⁇ m and 150 ⁇ m. In the case where these vectors are nanoparticulate vectors, their diameter is preferably between 0.1 ⁇ m and 0.5 ⁇ m and, in the case where these vectors are microparticulate vectors, their diameter is preferably between 1 ⁇ m and 50 ⁇ m. Moreover, the micro or nanoparticulate vectors according to the invention are loaded or uncharged.
- these vectors When these vectors are loaded, they are advantageously cationic.
- these vectors are fixed not only on the skin of animals but also on the hairs of their coat. They provide a regular and controlled release of mono- or oligosaccharides and / or alkylpolyglucoside on the surface of the skin and on the hairs.
- a mechanical action for example cleaning the animal, the benefits of the composition according to the invention are retained. This gradual release effect allows a maintenance in time of the action of mono- or oligosaccharides and / or alkylpolyglucoside on the adhesion of bacteria.
- micro or nanoparticulate vectors according to the invention When the micro or nanoparticulate vectors according to the invention are not charged, they are said to be nonionic. In this case, in addition to the aforementioned prolonged release effect, their presence promotes the diffusion of mono- or oligosaccharides and / or alkylpolyglucoside through the skin. Also, when the mono- or oligosaccharides and / or the alkylpolyglucoside present in the vectors have an inhibitory effect on the activation of keratinocytes and on the secretion of TNF- ⁇ , the effects of reducing cutaneous inflammation are improved.
- the composition according to the invention comprises both cationic micro- or nanoparticulate vectors and nonionic micro- or nanoparticulate vectors.
- the interest lies in the respective contribution of each type of vector to the decrease of the adhesion of the bacteria.
- the mono- or Free oligosaccharides (non-vectorized) and / or free alkylpolyglucoside have a direct and immediate action on the adhesion of bacteria.
- the cationic micro- or nanoparticulate vectors of the composition allow a direct and prolonged action of the mono- or oligosaccharides and / or the alkylpolyglucoside on the adhesion of the bacteria whereas the nonionic micro- or nanoparticulate vectors also exert a anti-irritant effect that reduces inflammation of the skin and reduces the adhesion of bacteria.
- composition according to the invention has both an immunomodulatory effect improved by a better diffusion of mono- or oligosaccharides and / or alkylpolyglucosides encapsulated in nonionic micro- or nanoparticulate vectors through the skin, but also an anti-inflammatory action.
- -adhesive extended by the presence of mono- or oligosaccharides and / or alkylpolyglucosides encapsulated in cationic micro- or nanoparticulate vectors.
- composition according to the invention may furthermore comprise antiseptic agents, chelating agents, keratolytic, kératorégulateurs, antiseborrhéiques agents and cleaning or emollient agents.
- antiseptic agents that can be used in the composition according to the invention, mention may be made of chlorhexidine, hexachlorophene, parachlorometaxylenol, piroctone olamine and triclosan, alone or as a mixture.
- chelating agents that can be used in the composition according to the invention, mention may be made of diethylene triamine pentaacetic and ethylenediaminetetraacetate, taken alone or as a mixture.
- keratolytic agents kératorégulateurs or antiseborrhéigues being able to enter in the composition according to the invention
- cleaning or emollient agents that can be used in the composition according to the invention, mention may be made of linoleic acid, cocoglucoside, decyl glucoside, disodium cocoamphodiacetate, disodium laureth, docusate sodium, sodium stearate and sulfosuccinate, alone or as a mixture.
- topical compositions according to the invention are more particularly intended for the treatment of the skin and the mucous membranes and may be in the form of ointments, creams, milks, ointments, soaked swabs, syndets, solutions , gels, sprays, mousses, suspensions, lotions, shampoos, or washing bases.
- compositions are used as cosmetic or pharmaceutical products for veterinary use. More particularly, they are used for the hygiene of warm-blooded animals, for the control, for the prevention or for the treatment of irritative dermatitis, atopic dermatitis, keratoseborrhoeic syndrome, otitis externa, pyoderma or dermatitis in Malassez ⁇ has warm-blooded animals with peeling.
- the invention thus relates to the use of mono- or oligosaccharides for the preparation of a topical composition for the control aid or for the preparation of a medicament for the treatment of dermatitis irritation, atopic dermatitis, keratoseborrhoeic syndrome, otitis externa, pyoderma, or Malassezia dermatitis in warm-blooded animals with peel, as well as methods for the treatment of these skin conditions in warm-blooded animals with the use of a composition containing mono- or oligosaccharides.
- the choice of mono- or oligosaccharides and / or alkylpolyglucoside present in the composition is determined by the end use of the composition according to the invention.
- the composition according to the invention is a lotion comprising at least two specific monosaccharides, L-fucose and L-rhamnose, these monosaccharides being contained in Spherulites TM type vectors.
- the composition according to the invention is a solution comprising three monosaccharides, L-rhamnose, D-mannose and D-galactose.
- the composition is a shampoo comprising three monosaccharides, as described above, associated with an alkylpolyglucoside.
- Example 1 The present invention will now be illustrated by means of the following Examples 1 and 2: Example 1
- the three strains of Pseudomonas were collected from dogs with infectious otitis. Corneocytes were taken from six different healthy dogs using D-squame TM brand adhesive discs, marketed by CuDerm TM.
- Bacterial suspensions each containing one of the three P1, P2 or P3 strains and PBS (saline phosphate buffer) with or without monosaccharides at two concentrations (0.05% and 0.1%) were prepared. These suspensions were each placed on a layer of corneocytes. These layers were incubated in a humid chamber. After incubation, the corneocytes were washed and stained. Adherent Pseudomonas were then quantified by computer-assisted image analysis.
- PBS saline phosphate buffer
- the percentage of adhesion of the strains in the presence of monosaccharides is then calculated with respect to the percentage of adhesion of the strains without monosaccharides (positive control).
- the percentages of adhesion are compared for the three strains P1 to P3 relative to the positive control (100%).
- the average percentage inhibition for the three strains of Pseudomonas is 25.6% for D-galactose, 19.4% for D-mannose and 30.8% for L-rhamnose. It appears that each of the three monosaccharides limits the adhesion of Pseudomonas to the corneocytes. When the three monosaccharides are used in In combination, surprisingly, an average percent inhibition of 53.4% is observed.
- composition according to the invention There is therefore a conjugation of action when, according to the invention, a plurality of mono- or oligosaccharides, each having anti-adhesive properties are present in the composition. This is at least the case when the composition according to the invention comprises three mono- or oligosaccharides having these properties.
- Example 2 A study comparing the inhibition by alkylpolyglucosides (Plantaren TM 1200) of the adhesion of three different strains of Staphylococcus intermedius, S1, S2, S3, was conducted on canine corneocytes.
- Corneocytes were taken from different healthy dogs, having not undergone topical or systemic treatment in the three weeks prior to collection, using D-Squame TM brand adhesive discs, marketed by CuDerm TM.
- Bacterial suspensions each containing one of the three strains S1, S2 or S3 and PBS were made.
- the percentage of adhesion of the strains in the presence of saccharides is then calculated with respect to percentage of adhesion of strains without saccharides (positive control).
- the percentages of adhesion are compared for the three strs S1 to S3 compared to the positive control (100%).
- the mean percent inhibition for the three strains of Staphylococcus aureus is 47.71% for alkyl polyglucosides.
- alkylpolyglucosides limit the adhesion of Staphylococcus intermedus to the corneocytes.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0503291A FR2883750B1 (fr) | 2005-04-04 | 2005-04-04 | Compositions topiques et leurs utilisations |
| PCT/FR2006/000730 WO2006106220A2 (fr) | 2005-04-04 | 2006-04-04 | Compositions topiques comprenant plusieurs mono-et/ou oligosaccharides pour le traitement des maladies cutanees d ' animaux a sang chaud a pelage |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP1868618A2 true EP1868618A2 (fr) | 2007-12-26 |
Family
ID=35431411
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP06726173A Withdrawn EP1868618A2 (fr) | 2005-04-04 | 2006-04-04 | Compositions topiques comprenant plusieurs mono-et/ou oligosaccharides pour le traitement des maladies cutanees d ' animaux a sang chaud a pelage |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US20080200427A1 (pt) |
| EP (1) | EP1868618A2 (pt) |
| JP (1) | JP5107229B2 (pt) |
| AU (1) | AU2006231248B2 (pt) |
| BR (1) | BRPI0612164A2 (pt) |
| FR (1) | FR2883750B1 (pt) |
| WO (1) | WO2006106220A2 (pt) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5737646B2 (ja) * | 2010-03-24 | 2015-06-17 | 森下仁丹株式会社 | 抗アレルギー剤 |
| US20170071979A1 (en) * | 2011-05-11 | 2017-03-16 | Veloce Biopharma, Llc | Composition and method for treating otitis |
| FR2989274B1 (fr) * | 2012-04-12 | 2016-02-26 | Biochimie Appliquee Soc | Composition cosmetique cutanee et/ou dermatologique destinee a limiter l'adhesion des bacteries pathogenes au niveau de la peau |
| PT3658160T (pt) | 2017-07-28 | 2021-08-26 | Isdin Sa | Utilização de ramnose e seus derivados como agentes antifúngicos |
| WO2020229446A1 (en) * | 2019-05-16 | 2020-11-19 | Unilever N.V. | Use of a sugar or sugar alcohol |
| DE102020133860A1 (de) | 2020-12-16 | 2022-06-23 | MNT Systeme GmbH | VERWENDUNG VON β-GALAKTOOLIGOSACCHRIDEN FÜR DIE HERSTELLUNG EINER KOSMETISCHEN UND/ODER PHARMAKOLOGISCH WIRKSAMEN ZUSAMMENSETZUNG |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB208690A (en) * | 1922-12-21 | 1924-12-15 | Pharmacia Ab | Pharmaceutical preparation and a method for producing the same |
| US4518517A (en) * | 1983-03-16 | 1985-05-21 | Colgate-Palmolive Company | Non-antimicrobial deodorant cleansing composition |
| US4690825A (en) * | 1985-10-04 | 1987-09-01 | Advanced Polymer Systems, Inc. | Method for delivering an active ingredient by controlled time release utilizing a novel delivery vehicle which can be prepared by a process utilizing the active ingredient as a porogen |
| FR2609397B1 (fr) * | 1988-02-23 | 1991-12-13 | Serobiologiques Lab Sa | Utilisation d'une substance ou composition de nature glucidique comme principe actif d'une composition dermatologique et/ou cosmetologique et/ou pharmaceutique et/ou stimulante cellulaire, et composition contenant une telle substance ou composition de nature glucidique |
| LU87410A1 (fr) * | 1988-12-20 | 1990-07-10 | Cird | Composition cosmetique ou pharmaceutique contenant des microspheres de polymeres ou de corps gras chargees d'au moins un produit actif |
| FR2649888B1 (fr) * | 1989-07-18 | 1994-08-26 | Exsymol Sa | Produits pour applications cutanees, a effets cosmetiques ou/et therapeutiques |
| US5002759A (en) * | 1989-07-25 | 1991-03-26 | Colgate-Palmolive Company | Oligosaccharide inhibition of Streptococcus pyogenes adhesion |
| US6087320A (en) * | 1989-09-14 | 2000-07-11 | Henkel Corp. | Viscosity-adjusted surfactant concentrate compositions |
| IL104399A0 (en) * | 1992-01-22 | 1993-05-13 | Mennen Co | Deodorant compositions containing materials for inhibiting bacterial adherence,method of use thereof,and method for determining materials that inhibit bacterial adherence |
| SE9200199L (sv) * | 1992-01-24 | 1993-07-25 | Rune Soeremark | Farmaceutisk komposition och dess anvaendning |
| DE19503423A1 (de) * | 1995-02-03 | 1996-08-08 | Beiersdorf Ag | Antiadhäsive Wirkstoffe |
| US6777003B1 (en) * | 1995-06-07 | 2004-08-17 | Cognis Corporation | Iodine complex of alkyl polyglycosides |
| US6057274A (en) * | 1997-08-22 | 2000-05-02 | Henkel Corporation | Antibacterial composition having enhanced tactile properties |
| CA2245254A1 (en) * | 1998-09-02 | 2000-03-02 | Soheyl Mottahedeh | Glycoside shampoo for treating psoriasis |
| US6458387B1 (en) * | 1999-10-18 | 2002-10-01 | Epic Therapeutics, Inc. | Sustained release microspheres |
| US6214339B1 (en) * | 2000-01-12 | 2001-04-10 | Michael A. Pellico | Di-enzymatic treatment of outer ear infection in dogs and cats |
| US6767508B1 (en) * | 2000-11-28 | 2004-07-27 | Kimberly-Clark Worldwide, Inc. | Nonwovens modified with alkyl polyglycoside surfactants |
| FR2820038B1 (fr) * | 2001-01-29 | 2004-07-02 | Dermaconcept Jmc | Composition dermatologique a usage veterinaire comprenant une base sphingoide |
| DE10163246A1 (de) * | 2001-12-21 | 2003-07-10 | Henkel Kgaa | Neue Verwendung von Apfelkernextrakten in kosmetischen oder pharmazeutischen Zusammensetzung |
| JP4509517B2 (ja) * | 2002-09-19 | 2010-07-21 | ロート製薬株式会社 | 黄色ブドウ球菌の皮膚付着を阻害し、かつ、表皮ブドウ球菌の皮膚付着を促進させる剤 |
-
2005
- 2005-04-04 FR FR0503291A patent/FR2883750B1/fr not_active Expired - Fee Related
-
2006
- 2006-04-04 JP JP2008504802A patent/JP5107229B2/ja not_active Expired - Fee Related
- 2006-04-04 AU AU2006231248A patent/AU2006231248B2/en not_active Ceased
- 2006-04-04 BR BRPI0612164-0A patent/BRPI0612164A2/pt not_active IP Right Cessation
- 2006-04-04 US US11/910,684 patent/US20080200427A1/en not_active Abandoned
- 2006-04-04 EP EP06726173A patent/EP1868618A2/fr not_active Withdrawn
- 2006-04-04 WO PCT/FR2006/000730 patent/WO2006106220A2/fr not_active Ceased
-
2010
- 2010-09-13 US US12/881,042 patent/US20100331276A1/en not_active Abandoned
-
2011
- 2011-05-09 US US13/103,429 patent/US20110212908A1/en not_active Abandoned
Non-Patent Citations (1)
| Title |
|---|
| C IBISCH ET AL: "IN VITRO ASSAYS FOR KERATINOCYTE ACTIVATION MODULATION BY FUCOSE, ARABINOSE AND RHAMNOSE", 1 January 2001 (2001-01-01), XP055284603, Retrieved from the Internet <URL:http://www.vetcontact.com/presentations/p_ibisch1/p_ibisch1.pdf> [retrieved on 20160629] * |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2006231248A2 (en) | 2006-10-12 |
| WO2006106220B1 (fr) | 2007-02-08 |
| US20100331276A1 (en) | 2010-12-30 |
| JP5107229B2 (ja) | 2012-12-26 |
| FR2883750A1 (fr) | 2006-10-06 |
| WO2006106220A3 (fr) | 2007-01-04 |
| WO2006106220A2 (fr) | 2006-10-12 |
| AU2006231248A1 (en) | 2006-10-12 |
| US20110212908A1 (en) | 2011-09-01 |
| BRPI0612164A2 (pt) | 2010-10-19 |
| AU2006231248B2 (en) | 2012-08-02 |
| JP2008534659A (ja) | 2008-08-28 |
| FR2883750B1 (fr) | 2009-07-31 |
| US20080200427A1 (en) | 2008-08-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60027455T2 (de) | Oligosaccharidealdonsäure und ihre topische verabreichung | |
| CN105407718A (zh) | 涂布的颗粒和包括其的组合物 | |
| EP0806935A2 (de) | Antiadhäsive wirkstoffe | |
| EP2911680B1 (fr) | Utilisation d'un extrait de lin provenant de l'hydrolyse des protéines de lin, en tant qu'agent actif antimicrobien | |
| EP2473042A1 (en) | Methods and compositions for disrupting biofilm utilizing chitosan-derivative compounds | |
| EP2739275B1 (fr) | Composition antiseptique | |
| FR2916634A1 (fr) | Association synergique vis-a-vis de la flore microbienne de l'epiderme humain et applications cosmetiques et pharmaceutiques | |
| JP7828056B2 (ja) | 口腔内病原細菌のバイオフィルム形成抑制剤、及び、口腔用製剤 | |
| US20110212908A1 (en) | Topical compositions and the use thereof | |
| EP2869827B1 (fr) | Utilisation d'un extrait de myrte en tant qu'agent anti-biofilm vis-a-vis de p. acnes | |
| US20190388309A1 (en) | Novel formulation for the elimination of cariogenic and opportunistic pathogens within the oral cavity | |
| EP4032542A1 (fr) | Composition antimicrobienne | |
| US20260091049A1 (en) | Halide-free ammonium silanes | |
| Audus et al. | Chlorhexidine effects on membrane lipid domains of human buccal epithelial cells | |
| WO2004078789A1 (fr) | Nouvel agent stimulant la liberation des beta-endorphines, compositions cosmetiques et/ou dermatologiques en contenant et leurs applications | |
| FR2769504A1 (fr) | Utilisation du miel en tant qu'agent diminuant l'adhesion des micro-organismes | |
| EP0310476B1 (fr) | Composition inhibitrice ou destructrice d'au moins un être vivant unicellulaire renfermant du fluor F- et du lithium Li+ | |
| WO2022157314A1 (en) | Hyaluronic acid for use on the skin | |
| Naseem et al. | A novel CNC-ZIF-8 nanocomposite exhibits potent antibiofilm activity against cariogenic Streptococcus mutans | |
| Hou et al. | Enzyme-powered PLGA micromotors for biofilm eradication and long-term regrowth inhibition | |
| FR3142886A1 (fr) | Composition cosmetique/dermatologique | |
| EP1283033A1 (fr) | Association d'alkylglycoside et de pyridinecarboxamide | |
| EP0884948A1 (fr) | Compositions antiseptiques a base de chlorobutanol et de chlorhexidine | |
| FR2740039A1 (fr) | Utilisation d'une substance inhibant la proteine d'adhesion d'un microorganisme, composition notamment cosmetique ou therapeutique contenant cette substance |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20071105 |
|
| AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
| DAX | Request for extension of the european patent (deleted) | ||
| 17Q | First examination report despatched |
Effective date: 20120125 |
|
| GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
| INTG | Intention to grant announced |
Effective date: 20180223 |
|
| RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: VIRBAC SA |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20180706 |